Scienza e Tecnologia
BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study
Bio Elpida President Gilles Devilliers stated that "Bio Elpida is excited and proud to contributing to BioVaxys' pharmaceutical bioproduction process development of BVX-0918A for the European Phase I clinical. The construction of a dedicated GMP clean room facility for cancer vaccine production is well in line with Bio Elpida's strategy to remaining a leader in this specific service offering."
Based in Vancouver , BioVaxys Technology Corp ., a British Columbia -registered clinical-stage biotechnology company, is developing viral and oncology vaccines based on its proprietary hapten-conjugated antigen platforms as well as immuno-diagnostics. The Company is developing BVX-0320, its SARS-CoV-2 vaccine candidate, and is advancing a clinical study of BVX-0918A, its cancer vaccine in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors, in late-stage ovarian cancer. Also in development is a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2. BioVaxys has two issued US patents and multiple pending US and international patents related to its cancer vaccine platform, and US/PCT patent applications for its viral vaccine platform and diagnostic technologies. BioVaxys common shares trade on the CSE under the stock symbol "BIOV" and are listed on the Frankfurt Bourse (FRA: 5LB) and the OTCQB Venture Market (OTCQB: BVAXF).
ON BEHALF OF THE BOARD
James Passin , CEO
+1 646 452 7054
Nikita Sashdev
Luna PR
info@lunapr.io
Logo: https://mma.prnewswire.com/media/1522337/BioVaxys_Technology_Corp_Bio_Elpida_Logo.jpg